Cancer Institute A national cancer institute
designated cancer center

Douglas W. Blayney

Publication Details

  • Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer JOURNAL OF CLINICAL ONCOLOGY Hassett, M. J., Silver, S. M., Hughes, M. E., Blayney, D. W., Edge, S. B., Herman, J. G., Hudis, C. A., Marcom, P. K., Pettinga, J. E., Share, D., Theriault, R., Wong, Y., Vandergrift, J. L., Niland, J. C., Weeks, J. C. 2012; 30 (18): 2218-2226

    Abstract:

    Gene expression profile (GEP) testing is a relatively new technology that offers the potential of personalized medicine to patients, yet little is known about its adoption into routine practice. One of the first commercially available GEP tests, a 21-gene profile, was developed to estimate the benefit of adjuvant chemotherapy for hormone receptor-positive breast cancer (HR-positive BC).By using a prospective registry data set outlining the routine care provided to women diagnosed from 2006 to 2008 with HR-positive BC at 17 comprehensive and community-based cancer centers, we assessed GEP test adoption and the association between testing and chemotherapy use.Of 7,375 women, 20.4% had GEP testing and 50.2% received chemotherapy. Over time, testing increased (14.7% in 2006 to 27.5% in 2008; P < .01) and use of chemotherapy decreased (53.9% in 2006 to 47.0% in 2008; P < .01). Characteristics independently associated with lower odds of testing included African American versus white race (odds ratio [OR], 0.70; 95% CI, 0.54 to 0.92) and high school or less versus more than high school education (OR, 0.63; 95% CI, 0.52 to 0.76). Overall, testing was associated with lower odds of chemotherapy use (OR, 0.70; 95% CI, 0.62 to 0.80). Stratified analyses demonstrated that for small, node-negative cancers, testing was associated with higher odds of chemotherapy use (OR, 11.13; 95% CI, 5.39 to 22.99), whereas for node-positive and large node-negative cancers, testing was associated with lower odds of chemotherapy use (OR, 0.11; 95% CI, 0.07 to 0.17).There has been a progressive increase in use of this GEP test and an associated shift in the characteristics of and overall reduction in the proportion of women with HR-positive BC receiving adjuvant chemotherapy.

    View details for DOI 10.1200/JCO.2011.38.5740

    View details for Web of Science ID 000305413200014

    View details for PubMedID 22585699

Stanford Medicine Resources:

Footer Links: